INMB

Inmune Bio, Inc.

Healthcare · Biotechnology

$109.13 sample

-1.32 (-1.20%) 1D

Market cap

$399.9B

Price as of

2026-10-15

Latest filing

8-K · 2026-09-29

Alerts

8

Price$109.13 +3.25% 3M daily closessample

112.27103.10

2026-07-202026-08-112026-09-022026-09-232026-10-15

purchase / approvalsale / rejectionfiling / neutral

Latest events

Filings, trades, FDA; newest first

Oct 05INSInsider buy: General Counsel
Sep 29SEC10-Q filed
Sep 18INSInsider sell: Chief Financial Officer
Sep 09SECDEF 14A filed
Sep 02INSInsider buy: Director
Aug 28INSInsider sell: 10% owner
Aug 21SEC8-K filed: material event
Aug 18SECForm 144 filed

Sign up to see the real INMB record →

Company facts

SEC EDGAR registration

Name: Inmune Bio, Inc.
Sector: Healthcare
Industry: Biotechnology
Smart-money score: +35sample, -100 to +100
Reporting currency: USD

Who is positioning in INMB

sample

Insiders: 18 insider transactions over 90 days, net selling, $60.1M
Congress: 4 members traded over 90 days
Institutions · 13F: 39 funds hold $8.3B
Activists · 13D/G: No 13D/13G activist filings on record

How are the fundamentals trending?

sample, by period end

Revenue$14.6B +13.1% y/y

Q4 2024Q3 2026

Inventory$8.4B +3.8% y/y

Q4 2024Q3 2026

Accounts receivable$6.8B +18.2% y/y

Q4 2024Q3 2026

Total debt$17.7B +19.9% y/y

Q4 2024Q3 2026

Peers

sample

Sample peer A: $124.6B -10.5% 3M
Sample peer B: $288.0B +0.2% 3M
Sample peer C: $233.5B -4.2% 3M
Sample peer D: $210.9B +0.7% 3M
Sample peer E: $66.7B +3.8% 3M